What is the recommended method to test for airborne viruses?

Testing for Airborne Viruses

Use high-efficiency air sampling (gelatin filter or electrostatic/enriching concentrators) followed by nucleic acid amplification testing (RT‑PCR/NAAT) on the captured material; prioritize nasopharyngeal RT‑PCR from symptomatic persons for clinical decisions affecting morbidity, mortality, and quality of life. 1, 2, 3, 4

Stepwise Recommendation (optimize for morbidity/mortality/QoL)

• Clinical action first (highest impact):

  • If a person is ill or exposed, collect a nasopharyngeal swab and run pathogen-specific NAAT (e.g., influenza, RSV, SARS‑CoV‑2); molecular assays outperform antigen tests for clinical decisions and treatment initiation 1.
  • Rationale: Direct patient testing guides antivirals/isolation and changes outcomes; routine noninfluenza multiplex testing has low-quality evidence for outcome benefit, so target testing to pathogens with available therapy or infection-control impact 1.

• Environmental air testing (surveillance/early warning; not a substitute for patient testing):

  1. Sampler selection (prefer high recovery and enrichment):
     • Electrostatic/enriching concentrators (e.g., HEPC) for 10–20 L/min with high enrichment and preserved viability; detect influenza A in 10 minutes sampling 3.
     • Growth-based virus aerosol concentrator (GVC) at up to 6 L/min with >90% viable recovery; rapid on-site detection via qPCR or plaque assay 5.
     • Gelatin filter samplers (e.g., MD8) at 20–50 L/min; validated protocol with ~80% recovery and qPCR readout; better precision at lower flows for low concentrations 4.
  2. Assay on collected sample:
     • RT‑qPCR/NAAT for target viruses (influenza, RSV, coronaviruses, adenovirus); immunosensors may provide 30‑min readouts but can be species-dependent 6, 3.
  3. Placement and duration:
     • Position samplers in airflow recirculation zones (not stagnant areas) to maximize detectable load; use facility airflow mapping/CFD if possible 7.
     • Sample at sufficient volume/time to exceed assay LOD; adjust flow down for low expected concentrations to improve precision 4.
  4. Interpretation and action:
     • Use positive air results to trigger targeted human testing, ventilation upgrades, masking, and occupancy control; do not make patient-level treatment decisions from air data alone (risk of false negatives/positives, no direct correlation to individual infection risk) 1, 8.

Key Evidence Framing

• Guideline anchor:
  • ATS/IDSA: For suspected CAP, test influenza by molecular NAAT; evidence for routine noninfluenza viral testing is low-quality for outcome improvement—apply selectively when it will change management 1.
• Laboratory considerations:
  • Multiplex panels may miss or underperform for some targets; singleplex NAATs can be more sensitive for specific viruses 2.
  • Upper-airway tests may miss lower-tract disease in critical/immunocompromised patients—consider lower-tract sampling if clinically indicated 1.
• Air sampling science:
  • Modern electrostatic/enriching and growth-based concentrators markedly increase recovery and speed, enabling near–real-time surveillance 3, 5, 6.
  • Standardized protocols with gelatin filters and RT‑qPCR provide reliable quantification at low loads; sampler placement critically affects detectability 4, 7.

Pitfalls and How to Avoid Them

• Pitfall: Relying on air testing to make patient treatment/isolation decisions.
  • Avoid: Always confirm with patient NAAT; use air data for surveillance and engineering controls only 1.
• Pitfall: Poor sampler placement and insufficient sample volume.
  • Avoid: Place in recirculation zones; ensure adequate flow/time per validated protocols 7, 4.
• Pitfall: Overinterpreting negative air samples.
  • Avoid: Recognize spatial variability and detection limits; repeat sampling and verify airflow patterns 8, 7.
• Pitfall: Assuming multiplex panels cover all targets equally.
  • Avoid: Use targeted NAAT when a specific pathogen will change management; confirm critical results with singleplex assays if needed 2.

Minimal Implementation Algorithm

• Patient with symptoms/exposure: Nasopharyngeal RT‑PCR for actionable viruses (influenza/RSV/SARS‑CoV‑2); escalate to lower-tract sampling in ICU/immunocompromised if discordant 1.
• Facility surveillance:
  • Choose HEPC or GVC for rapid enrichment; or MD8+gelatin filter for standardized qPCR workflow 3, 5, 4.
  • Place in airflow recirculation zones; sample 10–30 minutes at validated flows; run RT‑qPCR panel; act on positives with targeted human testing and ventilation controls 7, 4.